Our initial studies focused on acute pain.

Pain - in all its manifestationsThe LMAM laboratory has worked with the Department of Anesthesiology and Pain Management at Morges hospital Buchser heads, for ten years. Our initial studies focused on acute pain, and then we moved to the other known persistent, nagging ailments such as chronic pain. However, we have had very little objective information. Upon the intensity this type of pain .

Eric Buchser at the clinic at the Department in Morges, Switzerland, to participate in the study. But we are just starting to collect data. .

Doctors usually try to assess the severity of chronic pain with a detailed oral evaluation on a number of standard questionnaires. This method, however, gives a very static view of the condition of the patient - as he or she felt that day, at that time. There are other problems with this approach also. Patients rate their pain on a scale of 1 to 10, but obviously we do not all feel that a '5'in the same manner. And some patients, such as children or cognitively impaired are simply not able to describe or communicate their pain..AlzheimerVideoNews.comdebuts with an World Alzheimer Tag 2008 Special Report, discussion the key developments in the year 2008 appeared in the range of Alzheimer's research. The new report, either in a video news review and in paper form Alzheimer Videos News. Different innovative therapeutic to tackle the emerging new objectives into Alzheimer's disease. Therapeutic therapeutics the center in the 2008 after the failure of the Celebrities anti-amyloid investigational product tramiprosate and Fluriza .

Under these agent of etanercept is unique because it was conceived an abnormality of an abnormality the immune system in Alzheimer disease identified that can impair brain function. Resistance anomaly is an excess the molecule TNF in cerebrospinal fluid is assumed that disrupt with brain cells communicate in Alzheimer 's disease and related dementias.